Follicular Lymphoma

Follicular lymphoma (FL) is a slow-growing yet incurable form of non-Hodgkin's lymphoma (NHL), representing approximately 20-25% of NHL cases in the US. While many patients achieve remission with initial therapy, FL is characterized by cycles of relapse and retreatment. For those with relapsed or refractory (R/R) disease, the duration of response typically shortens with each treatment line. Advances in therapy, including immunochemotherapy, targeted agents, bispecific antibodies, and chimeric antigen receptor (CAR) T-cell therapy, have expanded treatment options for patients with R/R FL. However, navigating therapy selection remains complex, requiring careful consideration of disease aggressiveness, prior treatments, and individual patient factors. As treatment options evolve, ongoing research is also refining strategies for optimizing sequencing and combination therapies. Clinical trials continue to explore novel treatment combinations and sequencing strategies to improve long-term outcomes, particularly for patients with early relapse or high-risk disease. 

Effective management of FL extends beyond treatment selection to include comprehensive, patient-centered care. Multidisciplinary coordination, timely access to emerging therapies, and clinical trial enrollment play key roles in optimizing patient outcomes. Shared decision-making is essential, empowering patients to weigh the risks, benefits, and quality-of-life implications of different treatment options. Additionally, addressing barriers such as financial toxicity and geographic disparities in access to advanced therapies remains a priority. Strengthening care pathways and integrating supportive services can help ensure that patients receive guideline-directed care while maintaining their overall well-being throughout the treatment journey. 

For more information on any of these resources, please contact the ACCC Provider Education department.